Leadiant Biosciences Revcovi’s (elapegademase-lvlr) Receives FDA Approval for Adenosine Deaminase Severe Combined Immune Deficiency (ADA-SCID) in Pediatric and Adult Patients

 Leadiant Biosciences Revcovi’s (elapegademase-lvlr) Receives FDA Approval for Adenosine Deaminase Severe Combined Immune Deficiency (ADA-SCID) in Pediatric and Adult Patients

Leadiant Biosciences Revcovi’s (elapegademase-lvlr) Receives FDA Approval for Adenosine Deaminase Severe Combined Immune Deficiency (ADA-SCID) in Pediatric and Adult Patients

Shots:

  • The approval is based on two study results assessing Revcovi in patients and demonstrated in an increase in ADA activity, reduction in concentration of toxic metabolites with an improvement in total lymphocyte counts
  • Leadiant Biosciences’ Revcovi has received FDA’s Fast Track, Priority Review & ODD designation on 7 Jun, 2017, 27 Jun, 2018 & 19 Mar, 2015 respectively
  • Revcovi (elapegademase-lvlr) is a recombinant adenosine deaminase enzyme replacement therapy (ERT) indicated for ADA-SCID in pediatric and adult patients

Click here to read full press release/ article | Ref: Leadiant Biosciences | Image: Glassdoor

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post